Skip to navigation Skip to content

Clinical Trial: Cognitive Processing Speed Changes in Relapsing MS Treated With Ozanimod (RPC-1063)

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To improve cognition
Number of Subjects: 4
Medication: Ozanimod (RPC-1063)
Location: California
Institutions: SC3 Research - Pasadena Contact Information
Roxanne Cabading, ext. 799
(626) 250 2070
roxanne.cabading@neurosearch-usa.com

Funding:

Celgene

Description

A study to determine if oral ozanimod can affect cognitive processing speed in people with relapsing MS. All subjects will receive orally administered ozanimod HCl 1 mg. 

Please note: In response to the recent developments of the COVID-19 pandemic, sites are implementing measures to ensure the health, safety, and security of our staff, investigators, visitors, and study participants.

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.